Adults who switched between semaglutide and tirzepatide lost an average of 16% of their body weight over two years, compared with 10.9% for those who stayed on the drug they started, according to a Cleveland Clinic analysis of 20,486 patients presented at ObesityWeek 2026. People who stopped treatment altogether lost 3.9%.
The findings, reported by Healio, come from health records rather than a randomized trial. They show an association between treatment paths and weight change, not proof that switching itself produced the extra loss. The work is a conference presentation and has not been published in a peer-reviewed journal.